VENLO, The Netherlands,
October 16, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt:
QIA) plans as previously announced to release its report on results
for the third quarter and first nine months of 2017 on Monday, November 6 at approximately 22:00 Central
European Time (CET) / 16:00 Eastern
Time (EDT). A conference call is planned for Tuesday, November 7, at 15:00 CET / 9:00
EDT hosted by Peer M. Schatz,
Chief Executive Officer, and Roland Sackers, Chief Financial
Officer.
Conference Call and Webcast
Details
The conference call will begin at 15:00 CET /
9:00 EDT on November 7, 2017.
Interested parties may listen to the call by dialing: +1 760 294
1674 (U.S.), +44-203-059-5869 (UK), +49-69-566-037-000
(Germany)
The webcast will be accessible at
http://www.qiagen.com/de/about-us/investors/corporate-calendar.
A conference call replay will be available by using the following
link:http://services.choruscall.eu/links/qiagen171107.html
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the
leading global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharma and biotech companies) and Academia (life sciences
research). As of June 30, 2017,
QIAGEN employed approximately 4,600 people in over 35 locations
worldwide. Further information can be found at
http://www.qiagen.com.
Contact:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222
E-mail: ir@qiagen.com
Dr. Sarah Fakih
Associate Director Investor Relations
+49-210-329-11457
E-mail: ir@qiagen.com
SOURCE Qiagen N.V.